ADC Therapeutics SA (ADCT) vs Organigram Global (OGI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Organigram Global (OGI) has outperformed ADC Therapeutics SA (ADCT) over the past year, losing 51.0% versus a loss of 67.1%. Over five years, OGI leads with a -89.3% price change compared with -94.4% for ADCT. ADC Therapeutics SA is the larger company by market cap ($197.9 million vs $134.1 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADCT | OGI |
|---|---|---|
| Share price | $1.55 | $0.9303 |
| Market cap | $197.90M | $134.11M |
| 1-day change | +9.16% | -3.09% |
| YTD return | -59.77% | -42.86% |
| 1-year return | -67.05% | -51.02% |
| 5-year return | -94.42% | -89.29% |
| P/E ratio (TTM) | — | 2.16 |
| Forward P/E | — | 38.76 |
| EPS (TTM) | $-0.60 | $0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.98 | $2.24 |
| 52-week low | $0.78 | $0.853 |
| Distance from 52-week high | -68.87% | -58.47% |
| Analyst consensus | none | buy |
| Avg. price target upside | +114.82% | — |
| Average volume | 1.35M | 882.38K |
| Shares outstanding | 127.67M | 144.15M |
| Employees | 188 | 1,139 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OGI has outperformed ADCT by 16.0 percentage points over the past year.
About ADC Therapeutics SA
ADCT stock →ADC Therapeutics SA provides antibody drug conjugate (ADC) technology platform in Switzerland and the United States. Its flagship product includes ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S.
Health Care · Biotechnology: Pharmaceutical Preparations · 188 employees
About Organigram Global
OGI stock →Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,139 employees
ADCT vs OGI FAQ
Which is bigger, ADC Therapeutics SA or Organigram Global?
ADC Therapeutics SA (ADCT) is larger, with a market capitalization of $197.90M compared with $134.11M for Organigram Global (OGI).
Which stock has performed better over the past year, ADCT or OGI?
OGI returned -51.02% over the past 12 months, compared with -67.05% for ADCT (price return, excluding dividends). Past performance does not predict future results.
Are ADC Therapeutics SA and Organigram Global in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.